Abrdn Physical Platinum Shares ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.33 (market cap $1.93B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 13× Abrdn Physical Platinum Shares ETF's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PPLT | ROIV | |
|---|---|---|
Market Cap | $1.93B | $25.09B |
Volume | 2,947,556 | 5,738,571 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $41.81 |
52-Week Low | $13.73 | $16.04 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $21.36B |
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →